Development of innovative cancer immunotherapy on the basis of release from immune evasion in cervical cancer

基于解除宫颈癌免疫逃逸的创新癌症免疫疗法的发展

• 批准号: 20791173
• 负责人: KAWANO Kouichiro
• 金额: $ 2.75万
• 依托单位: Kurume University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2009
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20791173/
• 关键词: 婦人科腫瘍学; 腫瘍免疫学; がんワクチン; 婦人科腫瘍; 免疫抑制

We proposed an innovative strategy of cancer immunotherapy which not only activated the immune response but released from immune evasion in cervical cancer. In this study, infiltration of cytotoxic T lymphocytes (CTL) which had an important role for an elimination of tumor indicated a good prognosis. On the contrary, expression of pSTAT3 which affect an immune evasion associated with a poor prognosis. Although correlation between infiltration of CTL and the expression of pSTAT3 was not observed in this study, we verified that pSTAT3 up-regulated the production of the molecule which regress immune response such as VEGF and TGF-β in cervical cancer cell line. We expect the development of this innovative strategy for cancer immunotherapy by further investigation.

我们提出了一种创新的癌症免疫治疗策略，不仅激活了宫颈癌的免疫应答，而且还释放了宫颈癌的免疫逃逸。在这项研究中，细胞毒性T淋巴细胞（CTL）的浸润对消除肿瘤具有重要作用，表明预后良好。相反，影响免疫逃避的pSTAT 3的表达与不良预后相关。虽然本研究中未观察到CTL浸润与pSTAT 3表达之间的相关性，但我们证实pSTAT 3在宫颈癌细胞系中上调了使免疫应答消退的分子如VEGF和TGF-β的产生。我们期待通过进一步的研究，这种创新的癌症免疫治疗策略的发展。

项目成果

子宮頸部扁平上皮癌における活性化Stat3 (Signal transducer and activator of transcription 3)の発現は予後不良因子である

宫颈鳞状细胞癌中激活的 Stat3（信号转导和转录激活因子 3）的表达是不良预后因素

• 发表时间: 2008
• 作者: 竹本周二;牛嶋公生;津田尚武;河野光一郎;大田俊一郎;村上文洋;駒井幹;藤吉啓造;嘉村敏治
• 通讯作者: 嘉村敏治

Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma.

• DOI: 10.1038/sj.bjc.6605212
• 发表时间: 2009-09-15
• 期刊: British journal of cancer
• 影响因子: 8.8

Distinct patient responses to activation of T cells by free HER-2, G89(777-789)and protected LRMK-linked HER-2,{AE-39 [p776(Ava-774-788)], AE-47[(Ava-776-788)] and AE-37[p776(774-788)]} peptides could lead to development of personalized cancer vaccine

患者对游离 HER-2、G89(777-789) 和受保护的 LRMK 连接的 HER-2 激活 T 细胞的反应不同，{AE-39 [p776(Ava-774-788)]、AE-47[(Ava)

• 发表时间: 2009
• 期刊: Anticancer Res 29
• 作者: Li Y;Matsueda S;Efferson CL;Tsuda N;Kawano K;Gao Hui;Peoples GE;and Ioannides CG
• 通讯作者: and Ioannides CG